Swiss National Bank Sorrento Therapeutics, Inc. Transaction History

Swiss National Bank

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.74 - $1.83 $121,434 - $300,303	164,100 Added 17.79%	1,086,400 $966,000
Q3 2022 Nov 09, 2022	BUY	$1.51 - $2.88 $329,633 - $628,704	218,300 Added 31.01%	922,300 $1.45 Million
Q2 2022 Aug 09, 2022	BUY	$1.24 - $2.33 $19,716 - $37,047	15,900 Added 2.31%	704,000 $1.42 Million
Q1 2022 May 09, 2022	BUY	$2.0 - $4.9 $129,800 - $318,010	64,900 Added 10.41%	688,100 $1.6 Million
Q4 2021 Feb 08, 2022	BUY	$4.65 - $7.23 $92,535 - $143,877	19,900 Added 3.3%	623,200 $2.9 Million
Q3 2021 Nov 08, 2021	BUY	$7.41 - $10.99 $120,783 - $179,137	16,300 Added 2.78%	603,300 $4.6 Million
Q2 2021 Aug 06, 2021	BUY	$6.35 - $10.0 $485,140 - $764,000	76,400 Added 14.96%	587,000 $5.69 Million
Q1 2021 May 07, 2021	BUY	$7.03 - $16.51 $143,412 - $336,804	20,400 Added 4.16%	510,600 $4.22 Million
Q4 2020 Feb 05, 2021	BUY	$5.76 - $11.95 $1.11 Million - $2.3 Million	192,400 Added 64.61%	490,200 $3.35 Million
Q3 2020 Nov 09, 2020	BUY	$6.17 - $18.82 $213,482 - $651,172	34,600 Added 13.15%	297,800 $3.32 Million
Q2 2020 Aug 05, 2020	BUY	$1.73 - $6.76 $455,336 - $1.78 Million	263,200 New	263,200 $1.65 Million
Q4 2019 Feb 06, 2020	SELL	$1.45 - $4.17 $258,535 - $743,511	-178,300 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$1.86 - $5.94 $24,552 - $78,408	13,200 Added 8.0%	178,300 $847,000
Q4 2018 Feb 13, 2019	BUY	$2.01 - $4.24 $92,861 - $195,888	46,200 Added 38.86%	165,100 $396,000
Q2 2018 Aug 09, 2018	BUY	$4.75 - $8.0 $564,775 - $951,200	118,900 New	118,900 $856,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.